IP Library Granted Patent US 11,155,538
Granted Patent B2
US 11,155,538 · App. 16/937,005 · Granted Oct 26, 2021

Bicyclic CX3CR1 receptor agonists

Inventors: Paolo Pevarello (Pavia, IT); William J. Ray (Houston, TX); Mary Hamby (Houston, TX); Yaima Luzardo Lightfoot (Pearland, TX); Philip Jones (Houston, TX); Russell Thomas (Siena, IT); Chiara Liberati (Milan, IT); Domenica Torino (Praia a Mare, IT); Valentina Cusano (Naples, IT); Francesco Piscitelli (Marina di Strongoli, IT); Ali Munaim Yousif (Aversa, IT); Silvia Bovolenta (Milan, IT)
Assignees: Board of Regents, The University of Texas System; Axxam S.p.A.
C07D409/14C07C233/78C07D333/78C07D409/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,538
App. No.
16/937,005
Granted
Oct 26, 2021
Kind
B2
Abstract

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Claims (51)

1. A compound of the following formula (I)

or a stereoisomer thereof, or a salt thereof, wherein:

n is an integer between 1 and 4, forming a 6-10-membered cycloalkyl;

A is chosen from phenyl and heteroaryl, optionally substituted with one or more C 1 -C 3 alkyl substituents;

R 1 is chosen from hydrogen and C 1 -C 3 alkyl;

R 2 and R 3 are joined together via a group Y, such that R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 7 cycloalkyl or C 3 -C 7 heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl; or the C 3 -C 7 cycloalkyl or C 3 -C 7 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl;

Y is chosen from CH 2 and O;

R 4 is chosen from

R 5 and R 6 are each independently C 1 -C 6 alkyl;

R 7 , R 8 , R 9 , and R 10 are independently chosen from hydrogen and hydroxyl, or are independently chosen from C 1 -C 6 alkyl and C 1 -C 6 alkyloxy, either of which is optionally substituted with methoxy;

p is 1 or 2; and

X is chosen from CH 2 , O, or NR 11 where R 11 is hydrogen or C 1 -C 3 alkyl.

2. The compound as recited in claim 1 , or a stereoisomer thereof, or a salt thereof, wherein A is thiophene.

3. The compound as recited in claim 2 , or a stereoisomer thereof, or a salt thereof, wherein R 1 is chosen from hydrogen and methyl.

4. The compound as recited in claim 1 , or a stereoisomer thereof, or a salt thereof, wherein R 5 and R 6 are each independently C 1 -C 3 alkyl.

5. The compound as recited in claim 1 , or a stereoisomer thereof, or a salt thereof, wherein R 7 , R 8 , R 9 , and R 10 are independently hydrogen, hydroxyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, optionally substituted with methoxy.

6. The compound as recited in claim 1 , or a stereoisomer thereof, or a salt thereof, wherein X is chosen from CH 2 , O, or NH.

7. A compound of the following formula (I)

or a stereoisomer thereof, or a salt thereof, wherein:

n is an integer between 1 and 4, forming a 6-10-membered cycloalkyl;

A is chosen from phenyl and heteroaryl, optionally substituted with one or more C 1 -C 3 alkyl substituents;

R 1 is chosen from hydrogen and C 1 -C 3 alkyl;

R 2 and R 3 are joined together via a group Y, such that R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, fluorine, and methyl; or the C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl;

Y is chosen from CH 2 and 0;

R 4 is chosen from

R 5 and R 6 are each independently C 1 -C 6 alkyl;

R 7 , R 8 , R 9 , and R 10 are independently chosen from hydrogen and hydroxyl, or are independently chosen from C 1 -C 6 alkyl and C 1 -C 6 alkyloxy, either of which is optionally substituted with methoxy;

p is 1 or 2; and

X is chosen from CH 2 , O, or NR 11 where R 11 is hydrogen or C 1 -C 3 alkyl.

8. The compound as recited in claim 7 , or a stereoisomer thereof, or a salt thereof, wherein A is thiophene.

9. The compound as recited in claim 8 , or a stereoisomer thereof, or a salt thereof, wherein R 1 is chosen from hydrogen and methyl.

10. The compound as recited in claim 8 , or a stereoisomer thereof, or a salt thereof, wherein R 5 and R 6 are each independently C 1 -C 3 alkyl.

11. The compound as recited in claim 8 , or a stereoisomer thereof, or a salt thereof, wherein R 7 , R 8 , R 9 , and R 10 are independently hydrogen, hydroxyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, optionally substituted with methoxy.

12. The compound as recited in claim 8 , or a stereoisomer thereof, or a salt thereof, wherein X is chosen from CH 2 , O, or NH.

13. The compound as recited in claim 7 , or a stereoisomer thereof, or a salt thereof, wherein:

n is an integer between 1 and 4, forming a 6-10-membered cycloalkyl;

A is thiophene;

R 1 is chosen from hydrogen and methyl;

R 2 and R 3 are joined together via a group Y, such that R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, fluorine, and methyl; or the C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl;

Y is chosen from CH 2 and O;

R 4 is chosen from

R 5 and R 6 are independently C 1 -C 3 alkyl;

R 7 , R 8 , R 9 , and R 10 are independently chosen from hydrogen, hydroxyl, C 1 -C 3 alkyl, and C 1 -C 3 alkoxy, optionally substituted with methoxy;

p is 1 or 2; and

X is chosen from CH 2 , O, or NR 11 ; and

R 11 is C 1 -C 3 alkyl.

14. A compound chosen from any one of

or a stereoisomer thereof, or a salt thereof.

15. A pharmaceutical composition comprising a compound as recited in claim 1 , or a stereoisomer thereof, or a salt thereof, together with a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a compound as recited in claim 7 , or a stereoisomer thereof, or a salt thereof, together with a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising a compound as recited in claim 14 , or a stereoisomer thereof, or a salt thereof, together with a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2023
From: AXXAM S.P.A.
To: GOLGI NEUROSCIENCES S.R.L.
Reel/Frame 064507/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2021
From: PEVARELLO, PAOLO; THOMAS, RUSSELL; LIBERATI, CHIARA; TORINO, DOMENICA; CUSANO, VALENTINA; PISCITELLI, FRANCESCO; YOUSIF, ALI MUNAIM; BOVOLENTA, SILVIA
To: AXXAM S.P.A.
Reel/Frame 057566/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2021
From: RAY, WILLIAM J; HAMBY, MARY; LIGHTFOOT, YAIMA LUZARDO; JONES, PHILIP
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 056743/0034 →
Continuity (2)
Provisional Application 62877660 · Jul 23, 2019
Related Publication 20210024510A1 · Jan 28, 2021
Cited By (1)
US 12,258,337